Author

F. Hossain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

G. Monticone· 2 shared L. Miele· 2 shared S. Majumder· 2 shared A. Champhekar· 1 shared A. H. Boulares· 1 shared B. A. Osborne· 1 shared C. Gibson· 1 shared C. Loh· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Monticone

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Bioorthogonal labeling and enrichment of histone monoaminylation reveal its accumulation and regulatory function in cancer cell chromatin

N. Zhang, J. Wu, F. Hossain, H. Peng, H. Li, C. Gibson, M. Chen, H. Zhang, S. Gao, X. Zheng, Y. Wang, J. Zhu, J. J. Wang, I. Maze, Q. Zheng

This study develops chemical probes to label and enrich histone monoaminylation, revealing its enrichment in cancer tissues and its role in chromatin architecture regulation.

bioRxiv · Mar 20, 2024Biochemistry

The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer

M. Vigolo, C. Urech, S. Lamy, G. Monticone, J. Zabaleta, F. Hossain, D. Wyczechowska, L. Del Valle, R. O'Regan, L. Miele, R. Lehal, S. Majumder

This paper evaluates the efficacy and safety of CB-103, a Notch inhibitor, in preclinical breast cancer models, showing synergistic effects with existing therapies.

bioRxiv · Jul 6, 2023Cancer Biology

Targeting Cblb-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cells responses

G. Monticone, F. Csibi, S. Leit, D. Ciccone, A. Champhekar, J. E. Austin, D. A. Ucar, F. Hossain, Z. Huang, S. V. Ibba, A. H. Boulares, N. Carpino, S. Majumder, K. Xu, B. A. Osborne, , L. Miele

This study identifies a novel immunosuppressive pathway involving Cbl-b-mediated Notch1 degradation and shows that targeting this axis enhances CD8+ T-cell responses and anti-cancer immunity.

bioRxiv · Mar 15, 2022Cancer Biology

H2S Prodrug, SG-1002, Protects Against Myocardial Oxidative Damage and Hypertrophy via Induction of Cystathionine beta-Synthase and Antioxidant Proteins

R. K. Islam, E. Donnelly, F. Hossain, J. D. Gardner, k. N. islam

SG-1002, an H2S prodrug, reduces oxidative stress and hypertrophy in cardiac cells by increasing H2S, CBS, and antioxidant proteins.

bioRxiv · Mar 28, 2021 · PreprintCell Biology